{"work":{"id":"4b3fe92b-9ad0-4012-806d-96d2b281fccf","openalex_id":"https://openalex.org/W1997533142","doi":"10.1158/1535-7163.mct-08-0013","arxiv_id":null,"raw_key":null,"title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","authors":null,"authors_text":"Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M","year":2008,"venue":"Molecular Cancer Therapeutics","abstract":null,"external_url":"https://doi.org/10.1158/1535-7163.mct-08-0013","cited_by_count":1446,"metadata_source":"openalex","metadata_fetched_at":"2026-08-05T02:28:24.338817+00:00","pith_arxiv_id":null,"created_at":"2026-08-02T05:33:26.869397+00:00","updated_at":"2026-08-05T02:28:24.338817+00:00","title_quality_ok":true,"display_title":null,"render_title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling"},"hub":{"state":{"tier_text":"hub","tier":"hub","tier_reason":"10+ Pith inbound or 1,000+ external citations","pith_inbound_count":1,"external_cited_by_count":1446},"tier":"hub","role_counts":[],"polarity_counts":[],"runs":{},"summary":{},"graph":{},"authors":[]}}